Volume 27, Issue 2 - Public Disclosure

Why clinical study reports really matter

Authors: Michael Köhler, Beate Wieseler

Abstract

Download the full article

References

1. European Medicines Agency. European public assessment reports. [cited 2018 Jan 19]. Available from: Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124
2. Dwan K, Gamble C, Williamson PR, Kirkham JJ. Systematic review of the empirical evidence of study publication bias and outcome reporting bias: an updated review. PLoS One. 2013;8(7):e66844.
3. Hemminki E. Study of information submitted by drug companies to licensing authorities. Br Med J. 1980;280(6217):833–6.
4. Ioannidis JP. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA. 1998;279(4):281–6.
5. Song F, Parekh S, Hooper L, Loke YK, Ryder J, Sutton AJ, et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. 2010;14(8):iii, ix-xi, 1–193.
6. Jefferson TO, Demicheli V, Di Pietrantonj C, Jones M, Rivetti D. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2006(3):CD001265.
7. Doshi P. Neuraminidase inhibitors: the story behind the Cochrane review. BMJ. 2009;339:b5164.
8. Torjesen I. Cochrane review questions effectiveness of neuraminidase inhibitors. BMJ. 2014;348:g2675.
9. Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev. 2010(2):CD001265.
10. Institute for Quality and Efficiency in Health Care. Linagliptin: re-assessment of benefit according to § 35a, Para. 5b, Social Code Book V (dossier assessment). 2012 [cited 2018 Feb 28]. Available from: Available from: https://www.iqwig.de/en/projects-results/projects/drug-assessment/a12-11-linagliptin-re-assessment-of-benefit-according-to-35a-para-5b-social-code-book-v-dossier-assessment.2694.html
11. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, Von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475–83.
12. Wieseler B. Beyond journal publications: a new format for the publication of clinical trials. Z Evid Fortbild Qual Gesundhwes. 2017;120:3–8.
13. Jones CW, Safferman MR, Adams AC, Platts-Mills TF. Discrepancies between ClinicalTrials.gov recruitment status and actual trial status: a cross-sectional analysis. BMJ Open. 2017;7(10):e017719.
14. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med. 2013;10(12): e1001566; discussion e1001566
15. BMJ. Article types and preparation. [cited 2018 Feb 28]. Available from: Available from: http://www.bmj.com/about-bmj/resources-authors/article-types
16. PLOS Medicine. Submission guidelines: guidelines for specific study types; clinical trials. [cited 2018 Feb 28]. Available from: Available from: http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-clinical-trials
17. Loder E, Loder S, Cook S. Characteristics and publication fate of unregistered and retrospectively registered clinical trials submitted to The BMJ over 4 years. BMJ Open. 2018;8(2):e020037.
18. Taichman DB, Sahni P, Pinborg A, Peiperl L, Laine C, James A, et al. Data sharing statements for clinical trials: a requirement of the international committee of medical journal editors. PLoS Med. 2017;14(6):e1002315.
19. Naudet F, Sakarovitch C, Janiaud P, Cristea I, Fanelli D, Moher D, et al. Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine. BMJ. 2018;360:k400.
20. Gøtzsche PC, Jorgensen AW. Opening up data at the European Medicines Agency. BMJ. 2011;342:d2686.
21. European Medicines Agency. European Medicines Agency policy on publication of clinical data for medicinal products for human use. 2014 [cited 2018 Jan 19]. Available from: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/10/WC500174796.pdf
22. U. S. Food and Drug Administration. FDA Commissioner Scott Gottlieb, M.D., on new steps FDA is taking to enhance transparency of clinical trial information to support innovation and scientific inquiry related to new drugs. 2018 [cited 2018 Jan 19]. Available from: Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm592566.htm?utm_campaign=01162018_Statement_Transparency%20of%20clinical%20trial%20information&utm_medium=email&utm_source=Eloqua
23. Cohen D. Medical devices face tougher premarket testing under new EU laws. [cited 13.03.2018]. Available from: Available from: http://www.bmj.com/content/357/bmj.j1870
24. Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices, amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC, (2017).
25. Institute of Medicine. Sharing clinical trial data: maximizing benefits, minimizing risk. Washington, DC: National Academies Press; 2015.
26. Zarin DA, Tse T. Sharing Individual Participant Data (IPD) within the context of the Trial Reporting System (TRS). PLoS Med. 2016;13(1):e1001946.